CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2004-05-17): Endogenous cannabinoid may protect liver from fibrosis

Clinical

Endogenous cannabinoid may protect liver from fibrosis

Last Updated: 2004-05-17 16:15:01 -0400 (Reuters Health)

NEW ORLEANS (Reuters Health) - The endogenous cannabinoid anandamide seems to protect the liver from fibrosis by inducing necrotic cell death in hepatic stellate cells but not in hepatocytes, according to a presentation here Sunday at Digestive Disease Week.

Serum levels of anandamide (arachidonoyl ehanolamide), a lipid signaling molecule synthesized and released by endothelial cells, macrophages and platelets, are high in patients with liver disease, presenter Dr. Soeren V. Siegund told attendees. "Anadamide rapidly and dose dependently induces dell death in human and rat stellate cells," Dr. Siegund said.

In the study, microscopic morphology and staining patterns indicated that the mechanism of death was necrosis rather than apoptosis. Sublethal doses of anadamide inhibited stellate cell proliferation, even when cells were exposed to a strong inducer of cell proliferation.

Anandamide treatment increased formation of reactive oxygen species. It is apparent that the compound interacts with membrane cholesterol, noted the researcher, from Columbia University in New York, since depletion of cholesterol from cell membranes prevented reactive oxygen species formation and delayed anandamide -induced cell death.

However, it is not simply a matter of disrupting cell membrane, he added. "We did an experiment where we pretreated cells with MCD [a compound that depletes membrane cholesterol] and washed the cells and placed them in fresh medium. Still, cell death was increased when anandamide was added to the medium."

In an interview with Reuters Health, Dr. Siegmund noted that serum levels of anandemide are high in patients with viral or alcoholic hepatitis and in those with cirrhosis.

"It could be that anandamide metabolism is slower because of damage to hepatocytes, or it could be induced by activated immune cells," he suggested.

Normally, anandamide is metabolized very rapidly. Future studies will look at the effect of methanandamide, a more stable compound, and that of exogenous cannabinoids, such as THC, the active compound in marijuana. They also hope to examine the effects of these agents in vivo, in healthy animals and in those with liver disease.

But at this point, it is too soon to say that it actually inhibits fibrosis in vivo, he added.

Digestive Disease Week is the annual meeting of the American Gastroenterological Association, the American Association for the Study of Liver Diseases, the Gastroenterology Research Group, the Society for Surgery of the Alimentary Tract, and the American Society for Gastrointestinal Endoscopy.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.